BRIEF-Resverlogix explores potential of Apabetalone in phase 3 Betonmace clinical study
May 24 (Reuters) - Resverlogix Corp
* Potential of Apabetalone for treatment of high-risk diabetes and CKD is being explored in co's phase 3 Betonmace clinical study
* Says no increase in infections was reported in phase 2 trials
Source text for Eikon:
Further company coverage:
© Thomson Reuters 2017 All rights reserved.